Omega Fund Management is an investment fund managing more than $178 billion ran by Alexia Pearsall. There are currently 12 companies in Mrs. Pearsall’s portfolio. The largest investments include Replimune Inc and Nuvation Bio, together worth $96.8 billion.
As of 7th August 2023, Omega Fund Management’s top holding is 3,001,319 shares of Replimune Inc currently worth over $69.7 billion and making up 39.0% of the portfolio value.
Relative to the number of outstanding shares of Replimune Inc, Omega Fund Management owns less than approximately 0.1% of the company.
In addition, the fund holds 15,072,340 shares of Nuvation Bio worth $27.1 billion.
The third-largest holding is Alpine Immune Sciences Inc worth $20.9 billion and the next is Morphic Inc worth $17.8 billion, with 309,846 shares owned.
Currently, Omega Fund Management's portfolio is worth at least $178 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Omega Fund Management office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Alexia Pearsall serves as the Chief Financial Officer, Omega Fund Management, LLC at Omega Fund Management.
There are companies that Omega Fund Management is getting rid of from its portfolio.
Omega Fund Management closed its position in Imago Biosciences on 14th August 2023.
It sold the previously owned 3,018,737 shares for $45.4 million.
Alexia Pearsall also disclosed a decreased stake in Replimune Inc by 0.3%.
This leaves the value of the investment at $69.7 billion and 3,001,319 shares.
The two most similar investment funds to Omega Fund Management are American Trust Investment Advisors and Addison Advisors. They manage $179 billion and $178 billion respectively.
Omega Fund Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 69.9% of
the total portfolio value.
The fund focuses on investments in the United States as
58.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
25% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $398 million.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Replimune Group Inc |
30.01%
3,001,319
|
$69,690,627,000 | 39.05% |
| Nuvation Bio |
No change
15,072,340
|
$27,130,212,000 | 15.20% |
| Alpine Immune Sciences Inc |
No change
2,029,580
|
$20,864,082,000 | 11.69% |
| Morphic Holding Inc |
48.16%
309,846
|
$17,763,471,000 | 9.95% |
| Ikena Oncology |
No change
2,249,123
|
$14,754,247,000 | 8.27% |
| Theseus Pharmaceuticals |
No change
711,479
|
$6,638,099,000 | 3.72% |
| Kronos Bio, Inc. |
No change
3,818,283
|
$6,567,447,000 | 3.68% |
| Sana Biotechnology, Inc. |
No change
843,750
|
$5,028,750,000 | 2.82% |
| Spruce Biosciences, Inc. |
No change
2,161,022
|
$4,646,197,000 | 2.60% |
| Immunic, Inc. |
No change
1,788,160
|
$4,488,282,000 | 2.51% |
| Syros Pharmaceuticals Inc. |
No change
251,270
|
$791,500,000 | 0.44% |
| Senti Biosciences, Inc. |
No change
195,792
|
$122,762,000 | 0.07% |
| Imago Biosciences |
Closed
3,018,737
|
$45,432,000 | |
| Cincor Pharma |
Closed
560,985
|
$18,412,000 | |
| Gossamer Bio, Inc. |
Closed
1,500,000
|
$17,970,000 | |
| Paratek Pharmaceuticals Inc. |
Closed
1,971,241
|
$5,066,000 | |
| Omega Alpha Spac |
Closed
501,000
|
$4,975,000 | |
| Jounce Therapeutics Inc |
Closed
275,513
|
$645,000 | |
| Essa Pharma Inc |
Closed
328,196
|
$597,000 | |
| No transactions found | |||
| Showing first 500 out of 19 holdings | |||